Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126058801 | 12605880 | 1 | I | 20160720 | 20160729 | 20160729 | EXP | US-BAXTER-2016BAX039441 | BAXTER | WOODS R, READ A. CLINICAL MANAGEMENT OF RESISTANCE EVOLUTION IN A BACTERIAL INFECTION: A CASE STUDY. EVOLUTION, MEDICINE AND PUBLIC HEALTH. 2015 JAN 01;2015(1):281-288. | 56.00 | YR | F | Y | 0.00000 | 20160729 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126058801 | 12605880 | 1 | PS | CEFEPIME | CEFEPIME HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 50817 | SOLUTION FOR INFUSION | ||||||||||
| 126058801 | 12605880 | 2 | SS | CEFEPIME | CEFEPIME HYDROCHLORIDE | 1 | 50817 | ||||||||||||
| 126058801 | 12605880 | 3 | SS | VANCOMYCIN INJECTION, USP | VANCOMYCIN | 1 | Intravenous (not otherwise specified) | 50671 | SOLUTION FOR INFUSION | ||||||||||
| 126058801 | 12605880 | 4 | SS | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | Unknown | HIGH DOSE | 0 | ||||||||||
| 126058801 | 12605880 | 5 | SS | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | 0 | ||||||||||||
| 126058801 | 12605880 | 6 | SS | MEROPENEM. | MEROPENEM | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 126058801 | 12605880 | 7 | SS | MOXIFLOXACIN. | MOXIFLOXACIN | 1 | Unknown | 0 | |||||||||||
| 126058801 | 12605880 | 8 | SS | DAPTOMYCIN. | DAPTOMYCIN | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 126058801 | 12605880 | 9 | SS | DAPTOMYCIN. | DAPTOMYCIN | 1 | 0 | ||||||||||||
| 126058801 | 12605880 | 10 | SS | CLINDAMYCIN | CLINDAMYCINCLINDAMYCIN PHOSPHATE | 1 | Oral | 0 | |||||||||||
| 126058801 | 12605880 | 11 | C | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Unknown | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126058801 | 12605880 | 1 | Enterobacter infection |
| 126058801 | 12605880 | 2 | Staphylococcal infection |
| 126058801 | 12605880 | 3 | Staphylococcal infection |
| 126058801 | 12605880 | 4 | Enterobacter infection |
| 126058801 | 12605880 | 5 | Staphylococcal infection |
| 126058801 | 12605880 | 6 | Enterobacter infection |
| 126058801 | 12605880 | 7 | Staphylococcal infection |
| 126058801 | 12605880 | 8 | Staphylococcal infection |
| 126058801 | 12605880 | 9 | Enterococcal infection |
| 126058801 | 12605880 | 10 | Staphylococcal infection |
| 126058801 | 12605880 | 11 | Staphylococcal infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126058801 | 12605880 | LT |
| 126058801 | 12605880 | HO |
| 126058801 | 12605880 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126058801 | 12605880 | Bacterial infection | |
| 126058801 | 12605880 | Drug effect decreased | |
| 126058801 | 12605880 | Pathogen resistance |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |